Fibrosis: Oncodesign and TiumBio sign collaboration agreement for R&D of drug candidates
Under this agreement, Oncodesign will be responsible for identification, chemical synthesis and optimization of Nanocyclix® drug candidates and their early-stage analysis, while TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates. This initial phase of the collaboration will be funded by TiumBio.
Solo, offers from our innovative technical platforms
Home . Service . SOLO: offers from our innovative technical platforms
A wide range of distinct and diversified services
An extension of our innovation technology platforms, SOLO involves a wide range of distinct and diversified services. It covers an extensive spectrum of pharmaceutical expertise and the ability to design and carry out precise and ad hoc assessments in the discovery and development of new therapies. Drawing on our experience and expertise in the preclinical investigation of new therapeutic entities – with different mechanisms of action – in various indications, and given our mastery of cutting-edge translational technologies, our SOLO services are a guarantee of quality and excellence to meet various needs and specificities.
SOLO is also the answer for the development of new, relevant and more predictive disease models that are needed to better characterize and qualify exploratory and innovative therapeutic approaches. These developments can be carried out in partnership with our customers.